The mood at the outset was one of bullishness, given a gap-up opening, but bears took charge during the last half an hour of trade.
The rupee, which sank to over a two-month low during the day, reflected the stock market dithering. This followed a surging dollar after the Federal Reserve, at the end of its two-day monetary policy meet, kept the benchmark rate unchanged and announced a gradual end to the crisis-era stimulus programme.
It had declined 23.25 points in the previous two days.
The 50-share NSE Nifty, after moving between 10,158.90 and 10,058.60, finished lower by 19.25 points -- or 0.19 per cent -- at 10,121.90.
Asian markets turned off-colour after the US Fed move, giving investors the blues.
"Weakness in the rupee reflected markets' reaction to Fed outcome and potential rate hike in December. However, a sharp recovery was seen... FM's rhetoric on measures to review GDP has also served to arrest declines. Current developments to bring petroleum products under GST might enthuse investors," said Anand James, Chief Market Strategist, Geojit Financial Services Ltd.
The pharma counter attracted buying interest as the rupee weakened against the dollar, with most of the earnings denominated in the US currency. Cipla, Lupin and Sun Pharma logged gains by up to 4.04 per cent.
Dr Reddy's hit pay dirt, surging the most by 7.47 per cent to Rs 2,486.45 after the company said it has received Establishment Inspection Report (EIR) from the US health regulator USFDA for its formulations manufacturing facility in Andhra Pradesh.
Small-cap and mid-cap stocks moved in tandem with the benchmark indices, weakening by up to 0.51 per cent.
The BSE realty index was the biggest drag, down 2.28 per cent. Consumer durables, PSU and banking indices too weighed while healthcare and IT indices ended higher.
Foreign portfolio investors (FPIs) remained net sellers in the past several sessions, offloading equities worth Rs 1,185.40 crore. Domestic institutional investors (DIIs) bought shares to the tune of Rs 946.23 crore yesterday, according to provisional data.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
